Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biogen Inc.

< Previous 1 2 3 Next >
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB SAGE
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.